Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 22 February 2013 | By Louise Zornoza
Health Canada has announced that generics companies will have soon have timely access to new safety-labeling changes made to the Product Monographs (PM) for Canadian Reference Products (CRPs), pursuant to a Notifiable Change or Supplemental New Drug Submission made by a branded pharmaceutical company.
The changes, announced 21 February 2013, is intended to improve timeliness of information in order to facilitate the required corresponding updates to generic PMs. Manufacturers of authorized generic products will be required to file submissions to update their labeling within 30 days of the date of the posting on the table of the labeling change for the CRP.
The requirement applies to all companies with generic products, including those that are not marketed in Canada but have Drug Identification Numbers (DINs) assigned to them, as well as generic products on Intellectual Property (IP) hold.
The changes will be available to see through an online table hosted on Health Canada's website. Health Canada intends to assess the effectiveness of this new notification process at some later point in time, and has requested comments on this new initiative.
Tags: Branded, Generic, pharmaceutical, safety, drug